MBRX Stock Risk & Deep Value Analysis
Moleculin Biotech Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About MBRX Stock
We analyzed Moleculin Biotech Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MBRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is MBRX Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for MBRX?
- âš
Clinical trial failures or delays for lead candidates
- âš
Inability to secure sufficient funding leading to operational curtailment or bankruptcy
- âš
Further severe shareholder dilution from equity raises
- âš
Delisting from NASDAQ due to market capitalization or share price deficiencies
- âš
Competition from other novel oncology therapies
Unlock MBRX Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Moleculin Biotech Inc (MBRX) Do?
Market Cap
$25.26M
Sector
Healthcare
Industry
Biotechnology
Employees
17
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Visit Moleculin Biotech Inc WebsiteIs MBRX Stock Undervalued?
Unlock the full AI analysis for MBRX
Get the complete DVR score, risk analysis, and more
Does MBRX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
Highly fragile. While patents provide some protection, the inability to fund clinical development and commercialization severely limits the practical durability of any potential moat. Without successful market entry, IP offers no commercial advantage.
Moat Erosion Risks
- •Clinical trial failures invalidating the core intellectual property
- •Inability to secure funding to advance patented assets through development
- •Emergence of superior or faster-to-market competing therapies
- •Patent challenges or expirations
MBRX Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive MBRX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late May 2026)
- •Updates on Phase 1/2 clinical trials for annamycin in AML/STS (expected throughout 2026)
- •Potential small-scale equity financing announcements to extend cash runway
Medium-Term (6-18 months)
- •Initiation of a pivotal (Phase 3) trial for lead candidate, if Phase 2 data is compelling (highly dependent on funding)
- •Exploration of strategic partnerships for regional commercialization or specific indications
- •Data readouts from other pipeline candidates (e.g., WP1122, WP1066)
Long-Term (18+ months)
- •Regulatory approval of annamycin for an oncology indication (highly optimistic within 3-5 years)
- •Acquisition by a larger pharmaceutical company seeking a novel oncology asset
- •Significant market penetration if commercialization is achieved
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MBRX?
- ✓
Announcements of non-dilutive financing or significant strategic partnerships
- ✓
Positive Phase 2/3 clinical trial readouts for annamycin (especially in AML)
- ✓
Significant reduction in cash burn rates or extension of cash runway
Bull Case Analysis
See what could go right with Premium
Compare MBRX to Similar Stocks
See how Moleculin Biotech Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MBRX (Moleculin Biotech Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
